Why are novel TKIs needed for Ph+ ALL? What does this mean for patients?

During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Jorge Cortes, Augusta University, Augusta, US. We asked, Why are novel TKIs needed for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)? What does this mean for patients?

Cortes begins by explaining that despite a dramatic evolution in treatment, risks and outcomes for many patients can still improve. Cortes highlights hopes for better quality of life, higher cure rate, fewer toxicities, and reduced need for stem cell transplants. Finally, he discusses prospects for patients with Ph+ ALL.